These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 32212489)

  • 21. Serum lipid profiles: novel biomarkers predicting advanced prostate cancer in patients receiving radical prostatectomy.
    Zhang GM; Qin XJ; Zhang HL; Xiao WJ; Zhu Y; Gu CY; Dai B; Shi GH; Ye DW
    Asian J Androl; 2015; 17(2):239-44. PubMed ID: 25475662
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical significance of a large difference (≥ 2 points) between biopsy and post-prostatectomy pathological Gleason scores in patients with prostate cancer.
    Yoo C; Oh CY; Cho JS; Song C; Seo SI; Ahn H; Hwang TK; Cheon J; Lee KH; Kwon TG; Jung TY; Chung MK; Lee SE; Lee HM; Lee ES; Choi YD; Chung BH; Kim HJ; Kim WJ; Byun SS; Choi HY
    J Korean Med Sci; 2011 Apr; 26(4):507-12. PubMed ID: 21468257
    [TBL] [Abstract][Full Text] [Related]  

  • 23. LacdiNAc-Glycosylated Prostate-specific Antigen Density is a Potential Biomarker of Prostate Cancer.
    Inoue T; Kaneko T; Muramatsu S; Kimura H; Yoshino T; Goto T; Sawada A; Akamatsu S; Kobayashi T; Yamasaki T; Kaya T; Ogawa O
    Clin Genitourin Cancer; 2020 Feb; 18(1):e28-e36. PubMed ID: 31711843
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prostate-specific antigen density predicts extracapsular extension and increased risk of biochemical recurrence in patients with high-risk prostate cancer who underwent radical prostatectomy.
    Koie T; Mitsuzuka K; Yoneyama T; Narita S; Kawamura S; Kaiho Y; Tsuchiya N; Tochigi T; Habuchi T; Arai Y; Ohyama C; Yoneyama T; Tobisawa Y
    Int J Clin Oncol; 2015 Feb; 20(1):176-81. PubMed ID: 24771079
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Correlation of minute (0.5 MM or less) focus of prostate adenocarcinoma on needle biopsy with radical prostatectomy specimen: role of prostate specific antigen density.
    Allan RW; Sanderson H; Epstein JI
    J Urol; 2003 Aug; 170(2 Pt 1):370-2. PubMed ID: 12853777
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Risk assessment for biochemical recurrence prior to radical prostatectomy: significant enhancement contributed by human glandular kallikrein 2 (hK2) and free prostate specific antigen (PSA) in men with moderate PSA-elevation in serum.
    Steuber T; Vickers AJ; Haese A; Becker C; Pettersson K; Chun FK; Kattan MW; Eastham JA; Scardino PT; Huland H; Lilja H
    Int J Cancer; 2006 Mar; 118(5):1234-40. PubMed ID: 16152616
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Clinically predictive factors of Gleason score upgrading in patients after radical prostatectomy].
    Zuo Q; Zhang F; Huang Y; Ma LL; Lu M; Lu J
    Beijing Da Xue Xue Bao Yi Xue Ban; 2016 Aug; 48(4):603-606. PubMed ID: 29263497
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prostate-specific antigen (PSA) isoform p2PSA significantly improves the prediction of prostate cancer at initial extended prostate biopsies in patients with total PSA between 2.0 and 10 ng/ml: results of a prospective study in a clinical setting.
    Guazzoni G; Nava L; Lazzeri M; Scattoni V; Lughezzani G; Maccagnano C; Dorigatti F; Ceriotti F; Pontillo M; Bini V; Freschi M; Montorsi F; Rigatti P
    Eur Urol; 2011 Aug; 60(2):214-22. PubMed ID: 21482022
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Investigative clinical study on prostate cancer part VIII: prolactin hormone and the pituitary-testicular-prostate axis at the time of initial diagnosis and subsequent cluster selection of the patient population after radical prostatectomy.
    Porcaro AB; Ghimenton C; Petrozziello A; Migliorini F; Romano M; Sava T; Caruso B; Cocco C; Antoniolli SZ; Lacola V; Rubilotta E; Monaco C; Comunale L
    Anticancer Res; 2012 Apr; 32(4):1499-506. PubMed ID: 22493393
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Improved risk stratification for biochemical recurrence after radical prostatectomy using a novel risk group system based on prostate specific antigen density and biopsy Gleason score.
    Freedland SJ; Wieder JA; Jack GS; Dorey F; deKernion JB; Aronson WJ
    J Urol; 2002 Jul; 168(1):110-5. PubMed ID: 12050502
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Preoperative prostate-specific antigen isoform p2PSA and its derivatives, %p2PSA and prostate health index, predict pathologic outcomes in patients undergoing radical prostatectomy for prostate cancer.
    Guazzoni G; Lazzeri M; Nava L; Lughezzani G; Larcher A; Scattoni V; Gadda GM; Bini V; Cestari A; Buffi NM; Freschi M; Rigatti P; Montorsi F
    Eur Urol; 2012 Mar; 61(3):455-66. PubMed ID: 22078333
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prediction of the Pathologic Gleason Score to Inform a Personalized Management Program for Prostate Cancer.
    Coley RY; Zeger SL; Mamawala M; Pienta KJ; Carter HB
    Eur Urol; 2017 Jul; 72(1):135-141. PubMed ID: 27523594
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Patients with Biopsy Gleason Score 3 + 4 Are Not Appropriate Candidates for Active Surveillance.
    Park J; Yoo S; Cho MC; Jeong CW; Ku JH; Kwak C; Kim HH; Jeong H
    Urol Int; 2020; 104(3-4):199-204. PubMed ID: 31694041
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Unilateral positive biopsies in low risk prostate cancer patients diagnosed with extended transrectal ultrasound-guided biopsy schemes do not predict unilateral prostate cancer at radical prostatectomy.
    Gallina A; Maccagnano C; Suardi N; Capitanio U; Abdollah F; Raber M; Salonia A; Scattoni V; Rigatti P; Montorsi F; Briganti A
    BJU Int; 2012 Jul; 110(2 Pt 2):E64-8. PubMed ID: 22093108
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The percentage of free prostate-specific antigen does not predict extracapsular disease in patients with clinically localized prostate cancer before radical prostatectomy.
    Melchior SW; Noteboom J; Gillitzer R; Lange PH; Blumenstein BA; Vessella RL
    BJU Int; 2001 Aug; 88(3):221-5. PubMed ID: 11488733
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Ability of Prostate Health Index (PHI) to Predict Gleason Score in Patients With Prostate Cancer and Discriminate Patients Between Gleason Score 6 and Gleason Score Higher Than 6-A Study on 320 Patients After Radical Prostatectomy.
    Dolejsova O; Kucera R; Fuchsova R; Topolcan O; Svobodova H; Hes O; Eret V; Pecen L; Hora M
    Technol Cancer Res Treat; 2018 Jan; 17():1533033818787377. PubMed ID: 30021484
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prostate volumes derived from MRI and volume-adjusted serum prostate-specific antigen: correlation with Gleason score of prostate cancer.
    Karademir I; Shen D; Peng Y; Liao S; Jiang Y; Yousuf A; Karczmar G; Sammet S; Wang S; Medved M; Antic T; Eggener S; Oto A
    AJR Am J Roentgenol; 2013 Nov; 201(5):1041-8. PubMed ID: 24147475
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of concordance of Gleason score between prostate biopsy and radical prostatectomy.
    Mansouri N; Msakni I; Gargouri F; Khiari R; Bouziani A; Laabidi B
    Tunis Med; 2018 Jul; 96(7):430-436. PubMed ID: 30430487
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Limitations in Predicting Organ Confined Prostate Cancer in Patients with Gleason Pattern 4 on Biopsy: Implications for Active Surveillance.
    Perlis N; Sayyid R; Evans A; Van Der Kwast T; Toi A; Finelli A; Kulkarni G; Hamilton R; Zlotta AR; Trachtenberg J; Ghai S; Fleshner NE
    J Urol; 2017 Jan; 197(1):75-83. PubMed ID: 27457260
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Single small focus of prostate adenocarcinoma (< or = 1 mm and too small for grading) and clinical significant disease after radical prostatectomy.
    Taverna G; Colombo P; Seveso M; Giusti G; Piccinelli A; Benetti A; Graziotti P
    Arch Ital Urol Androl; 2006 Jun; 78(2):57-60. PubMed ID: 16929604
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.